CR20110279A - Derivados de piridina y pirimidina como inhibidores de fosfodiesterasa 10 - Google Patents

Derivados de piridina y pirimidina como inhibidores de fosfodiesterasa 10

Info

Publication number
CR20110279A
CR20110279A CR20110279A CR20110279A CR20110279A CR 20110279 A CR20110279 A CR 20110279A CR 20110279 A CR20110279 A CR 20110279A CR 20110279 A CR20110279 A CR 20110279A CR 20110279 A CR20110279 A CR 20110279A
Authority
CR
Costa Rica
Prior art keywords
piridine
pyrimidine derivatives
phosphodiesterase inhibitors
pyrimidine
compounds
Prior art date
Application number
CR20110279A
Other languages
English (en)
Inventor
Jennifer R Allen
Kaustav Biswas
Frank Chavez
Ning Chen
Frenel Fils Demorin
James R Falsey
Mike Frohn
Paul Harrington
Daniel B Horne
Essa Hu
Matthew R Kaller
Roxanne Kunz
Holger Monenschein
Tom Nguyen
Alex Pickrell
Andreas Reichelt
Shannon Rumfelt
Rob Rzasa
Kelvin Sham
Guomin Yao
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CR20110279A publication Critical patent/CR20110279A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención se refiere a compuestos de piridina y pirimidina y composiciones que los contienen, y proceso para preparar tales compuestos.
CR20110279A 2008-11-14 2011-05-26 Derivados de piridina y pirimidina como inhibidores de fosfodiesterasa 10 CR20110279A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11459508P 2008-11-14 2008-11-14
US16621509P 2009-04-02 2009-04-02

Publications (1)

Publication Number Publication Date
CR20110279A true CR20110279A (es) 2011-09-22

Family

ID=41557471

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110279A CR20110279A (es) 2008-11-14 2011-05-26 Derivados de piridina y pirimidina como inhibidores de fosfodiesterasa 10

Country Status (17)

Country Link
US (2) US8318718B2 (es)
EP (1) EP2364306B1 (es)
JP (1) JP2012508777A (es)
KR (1) KR20110086603A (es)
AR (1) AR074343A1 (es)
AU (1) AU2009313773B2 (es)
BR (1) BRPI0921598A2 (es)
CA (1) CA2742833C (es)
CR (1) CR20110279A (es)
EA (1) EA201100749A1 (es)
ES (1) ES2413808T3 (es)
IL (1) IL212670A0 (es)
MA (1) MA32891B1 (es)
MX (1) MX2011005093A (es)
TN (1) TN2011000220A1 (es)
TW (1) TW201030001A (es)
WO (1) WO2010057126A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010059618A1 (en) 2008-11-21 2010-05-27 High Point Pharmaceuticals, Llc Adamantyl benzamide compounds
MY170610A (en) 2009-02-05 2019-08-20 Takeda Pharmaceuticals Co Pyridazinone compounds
EP2585462B1 (en) 2010-06-24 2020-02-26 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds as phosphodiesterases (pdes) inhibitors
US9029536B2 (en) 2010-08-04 2015-05-12 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
WO2012018058A1 (ja) 2010-08-04 2012-02-09 武田薬品工業株式会社 縮合複素環化合物
US9150588B2 (en) 2010-08-10 2015-10-06 Takeda Pharmaceutical Company Limited Substituted pyridazin-4(1H)-ones as phosphodiesterase 10A inhibitors
JP6106603B2 (ja) 2011-01-11 2017-04-05 スノビオン プハルマセウトイカルス インコーポレイテッド ヘテロアリール化合物及びその使用方法
CN103476757A (zh) 2011-02-18 2013-12-25 阿勒根公司 作为磷酸二酯酶10(pde10a)的抑制剂的取代的6,7-二烷氧基-3-异喹啉醇衍生物
JP5973990B2 (ja) * 2011-03-16 2016-08-23 武田薬品工業株式会社 縮合複素環化合物
SG10201801668WA (en) 2011-06-10 2018-03-28 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
TWI570122B (zh) 2011-06-22 2017-02-11 武田藥品工業股份有限公司 稠合雜環化合物之結晶
US8778941B2 (en) 2011-06-24 2014-07-15 Amgen Inc. TRPM8 antagonists and their use in treatments
KR20140045507A (ko) 2011-06-24 2014-04-16 암젠 인크 Trpm8 길항제 및 치료에서의 그의 용도
UA109735C2 (xx) * 2011-08-25 2015-09-25 Піримідинові інгібітори pde10
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
JPWO2014142322A1 (ja) 2013-03-15 2017-02-16 第一三共株式会社 ベンゾチオフェン誘導体
WO2015006689A1 (en) 2013-07-12 2015-01-15 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using pde10a inhibitors and methods to measure pde10a expression
MX2016003843A (es) 2013-09-27 2017-02-15 Nimbus Iris Inc Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
SG11201700439VA (en) 2014-07-31 2017-02-27 Pasteur Institut Korea 2-amino-benzimidazole derivatives and their use as 5-lipoxygenase and/or prostaglandin e synthase inhibitors
MY195201A (en) 2015-09-18 2023-01-11 Kaken Pharma Co Ltd Biaryl Derivative and Medicine Containing Same
CN110563664A (zh) * 2019-07-23 2019-12-13 上海合全药物研发有限公司 外消旋体(4as,7s,7as)-叔丁基-7-羟基六氢环戊二烯[b][1,4]噁嗪-4(4ah)-甲酸基酯制法
KR20240007205A (ko) * 2021-05-12 2024-01-16 베링거 인겔하임 인터내셔날 게엠베하 cGAS 억제제로서의 N-연결된 사이클릭 치환체를 갖는 피리딘 유도체

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4198417A (en) * 1979-01-10 1980-04-15 American Hoechst Corporation Phenoxyphenylpiperidines
EP1401831A1 (en) * 2001-07-03 2004-03-31 Chiron Corporation Indazole benzimidazole compounds as tyrosine and serine/threonine kinase inhibitors
MXPA05010627A (es) 2003-04-04 2005-12-12 Lundbeck & Co As H Derivados de 4-(2-feniloxifenil)-piperidina o 1,2,3,6-tetrahidropiridina como inhibidores de la recaptacion de serotonina.
DE10337942A1 (de) * 2003-08-18 2005-03-17 Merck Patent Gmbh Aminobenzimidazolderivate
DE10344223A1 (de) 2003-09-24 2005-04-21 Merck Patent Gmbh 1,3-Benzoxazolylderivate als Kinase-Inhibitoren
DE10349587A1 (de) * 2003-10-24 2005-05-25 Merck Patent Gmbh Benzimidazolylderivate
US7470712B2 (en) 2004-01-21 2008-12-30 Bristol-Myers Squibb Company Amino-benzazoles as P2Y1 receptor inhibitors
DE102005016634A1 (de) * 2005-04-12 2006-10-19 Merck Patent Gmbh Neuartige Aza-Hetercyclen als Kinase-Inhibitoren
RU2008107868A (ru) 2005-08-02 2009-09-10 Айрм Ллк (Bm) Соединения и композиции в качестве ингибиторов протеинкиназ
NL2000397C2 (nl) 2006-01-05 2007-10-30 Pfizer Prod Inc Bicyclische heteroarylverbindingen als PDE10 inhibitoren.
US7868177B2 (en) * 2006-02-24 2011-01-11 Amgen Inc. Multi-cyclic compounds and method of use
WO2008057280A1 (en) 2006-10-27 2008-05-15 Amgen Inc. Multi-cyclic compounds and methods of use
WO2009081259A1 (en) 2007-12-21 2009-07-02 Pfizer Inc. Phenoxy-pyridyl derivatives
WO2010008739A2 (en) 2008-06-20 2010-01-21 Metabolex, Inc. Aryl gpr119 agonists and uses thereof

Also Published As

Publication number Publication date
CA2742833A1 (en) 2010-05-20
AU2009313773B2 (en) 2013-03-21
CA2742833C (en) 2013-12-31
US20100125062A1 (en) 2010-05-20
EP2364306A1 (en) 2011-09-14
US8318718B2 (en) 2012-11-27
KR20110086603A (ko) 2011-07-28
BRPI0921598A2 (pt) 2016-02-10
MA32891B1 (fr) 2011-12-01
US20130079325A1 (en) 2013-03-28
MX2011005093A (es) 2011-09-27
EA201100749A1 (ru) 2011-10-31
TW201030001A (en) 2010-08-16
AR074343A1 (es) 2011-01-12
ES2413808T3 (es) 2013-07-17
WO2010057126A1 (en) 2010-05-20
IL212670A0 (en) 2011-07-31
EP2364306B1 (en) 2013-04-24
JP2012508777A (ja) 2012-04-12
US8759532B2 (en) 2014-06-24
TN2011000220A1 (en) 2012-12-17
AU2009313773A1 (en) 2010-05-20

Similar Documents

Publication Publication Date Title
CR20110279A (es) Derivados de piridina y pirimidina como inhibidores de fosfodiesterasa 10
DOP2011000175A (es) Compuestos organicos
PH12014502169A1 (en) N-cyclylamides as nematicides
DOP2011000176A (es) Compuestos organicos
GB201106829D0 (en) Heterocyclic compounds
CR20110028A (es) Derivados de pirimidina como inhibidores de cinasa
CO6831982A2 (es) Pirazolo[4,3-d]pirimidinas útiles como inhibidores de cinasas
CR20110467A (es) Derivados de benzofuranilo como inhibidores de la glucoquinasa
BR112012032244A2 (pt) processo para preparar derivados de antranilamida com tetrazole-substituído e polimorfos cristalinos novos e derivados destes
BR112012010186A2 (pt) derivados de heteroarila contendo n como inibidores de quinase jak3.
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
BRPI0911208A2 (pt) moduladores inflamatórios antioxidantes: ácido oleanólico derivados com saturação no c-anel.
CR11427A (es) 2-fluoro-2 - desoxitetrahidrouridinas como inhibidores de citidina desaminasa
UY32611A (es) Compuestos de 1-cianoetilheterociclilcarboxamida sustituidos 750
MX2009007302A (es) Derivados de purina.
CR20110286A (es) Proceso para la preparacion de derivados de l-alanina protegidos
BR112012029647A2 (pt) novos derivados de pirimidinas
WO2008124129A3 (en) Treating hiv with a m-csf effector kinase inhibitor like imatinib
TN2015000261A1 (fr) Dérivés d'imidazopyridazine servant de modulateurs des recepteurs gabaa
EA201270280A1 (ru) Соединения пиримидина в качестве ингибиторов при лечении туберкулеза
DOP2015000059A (es) Amino-quinolinas como inhibidores de cinasa
SV2009003429A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica
UY29667A1 (es) Nuevos compuestos de piridina, composiciones farmaccuticas que los contienen, procedimientos de preparacinn y aplicaciones
CU20180028A7 (es) DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, ÚTILES COMO INHIBIDORES DUALES DE DYRK1/CLK1 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
MX2015013365A (es) Derivados de urea y su uso como inhibidores de proteina de union de acidos grasos (puag).

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)